Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease

Trial Profile

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 15 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2018 Results presented in an Aldeyra Therapeutics media release.
    • 25 Sep 2018 According to an Aldeyra Therapeutics media release, the company will hold a web-cast and conference call on 26th September 2018 to announce the results of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top